Growth Metrics

Soleno Therapeutics (SLNO) FCF Margin (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed FCF Margin for 5 consecutive years, with 53.1% as the latest value for Q4 2025.

  • For Q4 2025, FCF Margin changed N/A year-over-year to 53.1%; the TTM value through Dec 2025 reached 24.76%, changed N/A, while the annual FY2025 figure was 24.58%, 2988754.0% down from the prior year.
  • FCF Margin hit 53.1% in Q4 2025 for Soleno Therapeutics, down from 65.83% in the prior quarter.
  • Across five years, FCF Margin topped out at 2406.83% in Q1 2025 and bottomed at 38.63% in Q2 2025.